<?xml version='1.0' encoding='utf-8'?>
<document id="21406600"><sentence text="Effect of cyclosporine on the pharmacokinetics of aliskiren in healthy subjects."><entity charOffset="10-22" id="DDI-PubMed.21406600.s1.e0" text="cyclosporine" /><entity charOffset="50-59" id="DDI-PubMed.21406600.s1.e1" text="aliskiren" /><pair ddi="false" e1="DDI-PubMed.21406600.s1.e0" e2="DDI-PubMed.21406600.s1.e0" /><pair ddi="false" e1="DDI-PubMed.21406600.s1.e0" e2="DDI-PubMed.21406600.s1.e1" /></sentence><sentence text="To explore the clinical relevance of inhibition of multidrug resistance transporter 1 and organic anion transporting polypeptide transporter, a drug-drug interaction study was conducted using aliskiren and cyclosporine"><entity charOffset="192-201" id="DDI-PubMed.21406600.s2.e0" text="aliskiren" /><entity charOffset="206-218" id="DDI-PubMed.21406600.s2.e1" text="cyclosporine" /><pair ddi="false" e1="DDI-PubMed.21406600.s2.e0" e2="DDI-PubMed.21406600.s2.e0" /><pair ddi="false" e1="DDI-PubMed.21406600.s2.e0" e2="DDI-PubMed.21406600.s2.e1" /></sentence><sentence text=" This was an open-label, single-sequence, parallel-group, single-dose study in healthy subjects" /><sentence text=" Subjects (n = 14) first received aliskiren 75 mg orally (period 1), followed by aliskiren 75 mg + cyclosporine 200 mg (period 2) after a 7-day washout period, and aliskiren 75 mg + cyclosporine 600 mg (period 3) after a 14-day washout period"><entity charOffset="34-43" id="DDI-PubMed.21406600.s4.e0" text="aliskiren" /><entity charOffset="81-90" id="DDI-PubMed.21406600.s4.e1" text="aliskiren" /><entity charOffset="99-111" id="DDI-PubMed.21406600.s4.e2" text="cyclosporine" /><entity charOffset="164-173" id="DDI-PubMed.21406600.s4.e3" text="aliskiren" /><entity charOffset="182-194" id="DDI-PubMed.21406600.s4.e4" text="cyclosporine" /><pair ddi="false" e1="DDI-PubMed.21406600.s4.e0" e2="DDI-PubMed.21406600.s4.e0" /><pair ddi="false" e1="DDI-PubMed.21406600.s4.e0" e2="DDI-PubMed.21406600.s4.e1" /><pair ddi="false" e1="DDI-PubMed.21406600.s4.e0" e2="DDI-PubMed.21406600.s4.e2" /><pair ddi="false" e1="DDI-PubMed.21406600.s4.e0" e2="DDI-PubMed.21406600.s4.e3" /><pair ddi="false" e1="DDI-PubMed.21406600.s4.e0" e2="DDI-PubMed.21406600.s4.e4" /><pair ddi="false" e1="DDI-PubMed.21406600.s4.e1" e2="DDI-PubMed.21406600.s4.e1" /><pair ddi="false" e1="DDI-PubMed.21406600.s4.e1" e2="DDI-PubMed.21406600.s4.e2" /><pair ddi="false" e1="DDI-PubMed.21406600.s4.e1" e2="DDI-PubMed.21406600.s4.e3" /><pair ddi="false" e1="DDI-PubMed.21406600.s4.e1" e2="DDI-PubMed.21406600.s4.e4" /><pair ddi="false" e1="DDI-PubMed.21406600.s4.e2" e2="DDI-PubMed.21406600.s4.e2" /><pair ddi="false" e1="DDI-PubMed.21406600.s4.e2" e2="DDI-PubMed.21406600.s4.e3" /><pair ddi="false" e1="DDI-PubMed.21406600.s4.e2" e2="DDI-PubMed.21406600.s4.e4" /><pair ddi="false" e1="DDI-PubMed.21406600.s4.e3" e2="DDI-PubMed.21406600.s4.e3" /><pair ddi="false" e1="DDI-PubMed.21406600.s4.e3" e2="DDI-PubMed.21406600.s4.e4" /></sentence><sentence text=" Safety and pharmacokinetics were analyzed during each period" /><sentence text=" The primary objective was to characterize pharmacokinetics of aliskiren (single-dose and combination with cyclosporine)"><entity charOffset="63-72" id="DDI-PubMed.21406600.s6.e0" text="aliskiren" /><entity charOffset="107-119" id="DDI-PubMed.21406600.s6.e1" text="cyclosporine" /><pair ddi="false" e1="DDI-PubMed.21406600.s6.e0" e2="DDI-PubMed.21406600.s6.e0" /><pair ddi="false" e1="DDI-PubMed.21406600.s6.e0" e2="DDI-PubMed.21406600.s6.e1" /></sentence><sentence text=" The increases in area under the time-concentration curve from time 0 to infinity and maximum concentration associated with cyclosporine 200 mg or 600 mg were 4- to 5-fold and 2"><entity charOffset="124-136" id="DDI-PubMed.21406600.s7.e0" text="cyclosporine" /></sentence><sentence text="5-fold, respectively" /><sentence text=" Mean half-life increased from 25 to 45 hours" /><sentence text=" Based on comparison to literature, a single-dose of aliskiren 75 mg did not alter the pharmacokinetics of cyclosporine"><entity charOffset="53-62" id="DDI-PubMed.21406600.s10.e0" text="aliskiren" /><entity charOffset="107-119" id="DDI-PubMed.21406600.s10.e1" text="cyclosporine" /><pair ddi="false" e1="DDI-PubMed.21406600.s10.e0" e2="DDI-PubMed.21406600.s10.e0" /><pair ddi="false" e1="DDI-PubMed.21406600.s10.e0" e2="DDI-PubMed.21406600.s10.e1" /></sentence><sentence text=" Aliskiren 75 mg was well tolerated"><entity charOffset="1-10" id="DDI-PubMed.21406600.s11.e0" text="Aliskiren" /></sentence><sentence text=" Combination with cyclosporine increased the number of adverse events, mainly hot flush and gastrointestinal symptoms, with no serious adverse events"><entity charOffset="18-30" id="DDI-PubMed.21406600.s12.e0" text="cyclosporine" /></sentence><sentence text=" Two adverse events led to withdrawal (ligament rupture, not suspected to be study-drug related; and vomiting, suspected to be study-drug related)" /><sentence text=" Laboratory parameters, vital signs, and electrocardiographs showed no time- or treatment-related changes" /><sentence text=" As cyclosporine significantly altered the pharmacokinetics of aliskiren in humans, its use with aliskiren is not recommended"><entity charOffset="4-16" id="DDI-PubMed.21406600.s15.e0" text="cyclosporine" /><entity charOffset="63-72" id="DDI-PubMed.21406600.s15.e1" text="aliskiren" /><entity charOffset="97-106" id="DDI-PubMed.21406600.s15.e2" text="aliskiren" /><pair ddi="false" e1="DDI-PubMed.21406600.s15.e0" e2="DDI-PubMed.21406600.s15.e0" /><pair ddi="false" e1="DDI-PubMed.21406600.s15.e0" e2="DDI-PubMed.21406600.s15.e1" /><pair ddi="false" e1="DDI-PubMed.21406600.s15.e0" e2="DDI-PubMed.21406600.s15.e2" /><pair ddi="false" e1="DDI-PubMed.21406600.s15.e1" e2="DDI-PubMed.21406600.s15.e1" /><pair ddi="false" e1="DDI-PubMed.21406600.s15.e1" e2="DDI-PubMed.21406600.s15.e2" /></sentence><sentence text="" /></document>